Myriad [an error occurred while processing this directive]
[an error occurred while processing this directive]
[an error occurred while processing this directive]
HNPCC Cancer Risks

COLARIS® is the most accurate, highest-quality genetic test available to diagnose hereditary nonpolyposis colorectal cancer (HNPCC). People with an HNPCC gene mutation have greater than a 90 percent lifetime risk of developing some type of cancer.28 These individuals not only have an increased risk of colorectal and endometrial cancers, but also other cancers listed below:

Cancer Type Mutation
Carrier Risk1, 35
General
Population Risk
Colorectal Up to 82% 2%
Endometrial Up to 71% 1.5%
Stomach Up to 13% <1%
Ovarian Up to 12% 1%

* Patients with HNPCC may also have a slightly elevated risk of the following cancers when compared to the general population: ureter/renal pelvis, biliary tract, small bowel, pancreas, brain and sebaceous adenomas.

Individuals with HNPCC who have already been diagnosed with cancer also have an increased risk of developing a second cancer. In these patients, there is a 30 percent risk of a second cancer developing within 10 years of initial diagnosis and a 50 percent chance of a second cancer developing within 15 years of initial diagnosis.2, 20

» Managing Patients With HNPCC


COLARIS is a genetic test for hereditary nonpolyposis colorectal cancer (HNPCC)
A genetic test for hereditary nonpolyposis colorectal cancer (HNPCC)